SCHEMBL23218548

SCHEMBL23218548

COCCC(=O)C(C(=O)OC)c1cc(Br)ccc1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.40
TDP1 Q9NUW8 2/20 0.37
MAPT P10636 5/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
KMT2A Q03164 4/20 0.36
MEN1 O00255 2/20 0.36
TP53 P04637 1/20 0.36
KDM4E B2RXH2 5/20 0.36
POLB P06746 2/20 0.36
GLA P06280 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HTT P42858 2/20 0.35
GAA P10253 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MITF O75030 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218824 0.80 KDM4E (0.36) HPGDTDP1SMN1; SMN2LMNANPSR1
SCHEMBL29591689 0.80 KDM4E (0.36) HPGDTDP1SMN1; SMN2LMNANPSR1
SCHEMBL23218878 0.77 HPGD (0.40) HPGDTDP1MAPTSMN1; SMN2LMNA
SCHEMBL2402264 0.75 MAPT (0.39) HPGDMAPTSMN1; SMN2NPSR1KMT2A
SCHEMBL8321938 0.74 HPGD (0.47) HPGDTDP1MAPTSMN1; SMN2LMNA
SCHEMBL17274555 0.73 HPGD (0.44) HPGDTDP1MAPTSMN1; SMN2LMNA
SCHEMBL23606883 0.67 MEN1 (0.40) LMNANPSR1KMT2AMEN1POLB
SCHEMBL12610855 0.66 PTGS2 (0.40) HPGDKDM4EPOLBNPC1RAB9A
SCHEMBL8199897 0.66 ALDH1A1 (0.43) HPGDTDP1MAPTSMN1; SMN2KMT2A
SCHEMBL1509536 0.65 ALOX15 (0.45) HPGDTDP1MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB HPGD 695/4885TDP1 4644/4885MAPT 4793/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB HPGD 323/4885TDP1 3520/4885MAPT 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.